Clinical pharmacological trial of TM8001 for schizophrenia associated with carbonyl stress

Clinical pharmacological trial of TM8001 for schizophrenia associated with carbonyl stress - Clinical pharmacological trial of TM8001 for schizophrenia associated with carbonyl stress

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006398

Enrollment

Registered

2011-10-01

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia associated with carbonyl stress

Interventions

intervention taking TM8001

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: An inpatient over 20 years old or under 65 years of age. A patients diagnosed as schizophrenia according to DSMIVTR before one year from consent. A subjects with over 55.2ng/mL of plasma pentosidine. A patients showing over 60 or under 120 of PANSS. A patients with informed consent by own or representative family.

Exclusion criteria

Exclusion criteria: creatinin >2mg/dL or BUN > 25mg/dL. HbA1c > 6.1% and fetal blood suger > 126mg/dL or blood suger > 200mg/dL. AST, ALT over 2.5 fold of standard level. Total bilirubin > 3mg/dL. sever cardiac diseases, lung diseases, hepatic diseases, neurological diseases, hematological diseases, endocrine diseases,immune diseases, other sever diseases. History of anaphylaxis shock, drug allergy. History of taking aminophylline , teophylline, cholinteophylline, levodopa within 4 weeks before trail. History of taking ECT within 3 months before trail. Possible risk of suicide. History of cancer within 5 years before trail. Participating other trial. Pregnancy. Inappropriate regarded by the responsible doctor.

Design outcomes

Primary

Measure	Time frame
PANSS, BPRS	—

Secondary

Measure	Time frame
plasma pentosidine level	—

Countries

Japan

Contacts

Public ContactHiromi Idozawa

Tokyo Metropolitan Matsuzawa Hospital Department of Medicine

chiken-psy@matsuzawa-hp.metro.tokyo.jp81-3-3303-7211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026